New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif. , Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc.